Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag159 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 26.04.2026. Verfasst von Nobuyuki Takahashi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Carcinoma, Ductal, Breast. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Young Investigator Funding of the Japan Health Research Promotion Bureau.
Abstract (Originalsprache)
Background
The KEYNOTE-522 (KN522) trial demonstrated significantly improved outcomes with neoadjuvant chemotherapy (NAC) combined with pembrolizumab in high-risk triple-negative breast cancer (TNBC). However, the efficacy of this chemoimmunotherapy for histologically uncommon TNBC subtypes, such as invasive ductal carcinoma (IDC) with apocrine feature (IDCapo) or metaplastic carcinoma, remains unclear. Patients and methods This retrospective study examined clinicopathological characteristics and outcomes of patients with clinical stage II or III TNBC treated with either the KN522 regimen or conventional NAC without immunotherapy at the National Cancer Center Hospital East between August 2014 and December 2024. Patients pathologically diagnosed with IDC, IDCapo, or metaplastic carcinoma were included. We compared outcomes of the KN522 regimen among histologic subtypes and evaluated its efficacy versus conventional NAC in patients with IDCapo or metaplastic carcinoma.
Results
Seventy-two patients with TNBC received the KN522 regimen: 58 IDC, 10 IDCapo, and 4 metaplastic carcinoma. The pathological complete response (pCR) rate was significantly lower in IDCapo than in IDC (3/10 [30.0%] vs. 41/58 [70.7%], P = 0.027), and this difference remained after adjustment for clinical factors. There were no metaplastic carcinoma patients with pCR (0/4, 0%). Compared with conventional NAC, the KN522 regimen yielded a higher pCR rate in IDCapo (3/10 [30.0%] vs. 0/19 [0%], P = 0.033), but not in metaplastic carcinoma (0/4 [0%] vs. 1/10 [10.0%], P = 1.00).
Conclusion
The pCR rate of NAC with pembrolizumab was significantly lower in IDCapo than in IDC but was improved compared with conventional NAC. No meaningful benefit was observed in metaplastic carcinoma.
Implications for Practice
This study suggests that neoadjuvant chemoimmunotherapy can improve pathological complete response rate in invasive ductal carcinoma with apocrine feature, known as therapeutically resistant uncommon histology of the breast cancer. Pathological complete response rates of the neoadjuvant chemoimmunotherapy is dismal in metaplastic breast carcinoma, which sheds light to highly unmet need of novel therapeutic strategies for such aggressive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan.
- Minamiakatsuka Clinic, Mito, Ibaraki, 311-4153, Japan.
- Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan.
- Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan.
- Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan.
- Department of Breast Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan.
ORCID-Profile: Nobuyuki Takahashi, Chikako Funasaka, Nobuaki Matsubara, Yoichi Naito, Toru Mukohara
Förderung
- Young Investigator Funding of the Japan Health Research Promotion Bureau
Zitieren
APA
Takahashi, N., Funasaka, C., Shimura, M., Hirota, A., Uematsu, M., Fukuda, M., Baba, K., Mamishin, K., Nakajima, H., Kondoh, C., Harano, K., Matsubara, N., Hosono, A., Kawasaki, T., Onishi, T., Naito, Y., & Mukohara, T. (2026). Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag159
Vancouver
Takahashi N, Funasaka C, Shimura M, Hirota A, Uematsu M, Fukuda M, et al. Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag159
BibTeX
@article{Takahashi2026,
author = {Takahashi, Nobuyuki and Funasaka, Chikako and Shimura, Mai and Hirota, Akira and Uematsu, Mao and Fukuda, Misao and Baba, Kaede and Mamishin, Kanako and Nakajima, Hiromichi and Kondoh, Chihiro and Harano, Kenichi and Matsubara, Nobuaki and Hosono, Ako and Kawasaki, Toshikatsu and Onishi, Tatsuya and Naito, Yoichi and Mukohara, Toru},
title = {Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag159}
}
EUVIMED